Rapid Dose Therapeutics signs product supply agreement with Oakland Health Limited in UK


BURLINGTON, Ontario – (COMMERCIAL THREAD) – Rapid Dose Therapeutics Corp. (“RDT“or the”Society”) (CSE: DOSE), a Canadian biotech company that is revolutionizing drug delivery through innovation, entered into an agreement on Friday, November 26, 2021 with Oakland Health Limited (“Oakland Health”Functioning like “Therapeutic RD”) to supply QuickStrip ™ products to the UK and EU.

“This strategic partnership supports our business plan for rapid global expansion, introducing our new QuickStrip ™ technology and nutraceuticals in the UK, along with further expansion plans across the European Union,” said Mark Upsdell , CEO of Rapid Dose Therapeutics. “It is through our strategic partnerships with leading organizations such as RD Therapeutics that we will be able to raise awareness of our new delivery technology as it becomes more and more used, especially as a system. oral administration of vaccines. ”

RD Therapeutics is well positioned to maximize sales in these geographies, thanks to its strong relationships across the UK and EU in pharmacy and retail chains, essential for broad education and adoption of QuickStrip ™ products in these markets.

“We are very pleased to have been selected by Rapid Dose Therapeutics to bring their innovative products to the UK and EU markets,” said Ailene Thiel, CEO of RD Therapeutics. “This new technology will be well received in these markets as a truly innovative delivery mechanism, initially for nutraceuticals, with expansion into pharmaceuticals and vaccines to follow. We look forward to operating as RDT’s supply partners in the UK and Europe and we will support the marketing and sales of these exceptional products with scientific rigor and our in-depth knowledge of the markets we serve.

RD Therapeutics placed a first product order on Friday, December 3, 2021, including RDT-branded and white-label products in the lifestyle, health and wellness industries, for delivery in the first quarter of 2022.

About Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics is a Canadian biotechnology company that is revolutionizing drug delivery through innovation. The company’s flagship product, QuickStrip ™, is an orally soluble thin film, which can be infused with an endless list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, which are delivered quickly into the circulation. blood, causing rapid onset of the active ingredient.


About Oakland Health Limited operating as “RD Therapeutics”

Inspired by science, technology and clinical evidence, RD Therapeutics was formed by a multidisciplinary team of industry experts with global experience through technology, pharmaceutical and nutraceutical industries. The company’s professional trajectory has taught it the importance of being at the forefront of research and technological advances in product development to bring to market a unique range of products that will help create a society in which health and wellness are a way of life. within everyone’s reach.



Certain information contained in this press release may contain forward-looking information within the meaning of applicable securities laws. All statements contained in this press release that are not statements of historical fact can be considered as forward-looking statements. Forward-looking statements are often identified by words such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend”, “will”, “Could”, “are intended” to “,” are intended “or the negative of such terms and similar expressions. Statements containing forward-looking information, including, without limitation, with respect to the delivery of equipment and products using the QuickStrip ™ Product Delivery Method, generation of recurring revenue, as of date of this press release, the plans, estimates, forecasts, projections, expectations or beliefs of the management of RDT as to future events or results and are believed to be reasonable based on the information currently available to the management of RDT. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments relating to cannabis; the inability to access sufficient capital from internal and external sources, and / or the inability to access sufficient capital on favorable terms; the cannabis industry in Canada in general, income tax and regulatory matters; the ability to implement its business strategies; competetion; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that forward-looking statements, although considered reasonable by RDT management at the time of preparation, will prove to be correct, as there can be no assurance that the plans, intentions or expectations on which they are based. will come true. . Actual results and future events could differ materially from those anticipated in these forward-looking statements. Readers should not place undue reliance on forward-looking statements. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement.


About Author

Comments are closed.